Abstract-The aim of this new statement is to provide a comprehensive and evidence-based review of the scientific data evaluating the use of telemedicine for stroke care delivery and to provide consensus recommendations based on the available evidence. The evidence is organized and presented within the context of the American Heart Association's Stroke Systems of Care framework and is classified according to the joint American Heart Association/American College of Cardiology Foundation and supplementary American Heart Association Stroke Council methods of classifying the level of certainty and the class of evidence. Evidence-based recommendations are included for the use of telemedicine in general neurological assessment and primary prevention of stroke; notification and response of emergency medical services; acute stroke treatment, including the hyperacute and emergency department phases; hospital-based subacute stroke treatment and secondary prevention; and rehabilitation.

Computed tomography (CT) is an established tool for the diagnosis of ischemic or hemorrhagic stroke. Nonenhanced CT can help exclude hemorrhage and detect "early signs" of infarction but cannot reliably demonstrate irreversibly damaged brain tissue in the hyperacute stage of ischemic stroke. Further evaluation of patients with ischemic stroke should include differentiation between reversible and irreversible brain damage, which is essential for choosing an appropriate therapy. Perfusion CT provides information about brain perfusion, which permits differentiation of irreversibly damaged brain tissue from reversibly impaired "tissue at risk." CT angiography can help detect stenosis or occlusion of extra- and intracranial arteries. Multisection CT allows the combined use of all three imaging modalities-nonenhanced CT, perfusion CT, and CT angiography-to rapidly obtain comprehensive information regarding the extent of ischemic damage in acute stroke patients. Specific patterns of findings are typically seen in ischemic stroke and can be analyzed more accurately with the combined use of multisection CT and MR imaging. Nevertheless, prospective studies involving a large number of patients will be needed to ascertain the treatment of choice for patients with each of these patterns of findings.

Background and Purpose-Platelet activation plays a crucial role in the pathophysiology of cerebral ischemia. The aim of this study was to investigate the contribution of platelet activation and leukocyte-platelet interactions to the disease. Methods-One hundred thirty-five patients with transient ischemic attack (TIA) or stroke were enrolled in this single-center study. They underwent cranial computer tomography within 24 hours of clinical onset and after 3 months, and systemic venous blood samples were drawn. Platelet activation (CD62P expression), leukocyte activation (L-selectin expression), and the appearance of platelet-specific antigens on leukocytes as an index of platelet-leukocyte aggregation were measured by flow cytometric techniques in the acute state and at 3-month follow-up. Results-Patients with a completed stroke or TIA had significantly increased circulating platelet-leukocyte aggregates, increased P-selectin expression on platelets, and decreased L-selectin expression in the acute state compared with the control group (healthy volunteers). No differences in regard to the tested activation markers could be detected between patients with stroke or TIA in the acute phase of the disease. However, platelet and leukocyte activations were normalized after 3 months in patients with TIA, whereas leukocyte activation (reduced L-selectin expression) remained in stroke patients. Conclusions-In patients with TIA and completed stroke, platelet and leukocyte activation is substantially enhanced in the acute phase of the disease. The sustained leukocyte activation observed in stroke but not in TIA patients at 3-month follow up might play a pathophysiological role in the course of the disease.